These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 3457438)

  • 1. Pharmacokinetic studies on ara-C. With special emphasis on the cellular pharmacokinetics.
    Liliemark J
    Scand J Haematol Suppl; 1986; 44():41-50. PubMed ID: 3457438
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans.
    Wan SH; Huffman DH; Azarnoff DL; Hoogstraten B; Larsen WE
    Cancer Res; 1974 Feb; 34(2):392-7. PubMed ID: 4521089
    [No Abstract]   [Full Text] [Related]  

  • 3. [The pharmacokinetic study on cytarabine nanoparticle lyophilization injection in rabbits].
    Zhou J; Jiang XH; He L; Li CR; Yang JY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):145-7. PubMed ID: 16468665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
    Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
    Lopez JA; Beardsley GP; Krikorian JG; Mortara RW; Agarwal RP
    Cancer Res; 1983 Nov; 43(11):5190-3. PubMed ID: 6616454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma.
    Sato T; Morozumi M; Kodama K; Kuninaka A; Yoshino H
    Cancer Treat Rep; 1984 Nov; 68(11):1357-66. PubMed ID: 6498853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of terbutaline therapy.
    Andersson KE; Nyberg L
    Eur J Respir Dis Suppl; 1984; 134():165-70. PubMed ID: 6586476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.
    White JC; Hines LH; Rathmell JP
    Cancer Res; 1985 Jul; 45(7):3070-5. PubMed ID: 4005845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Plunkett W; Dixon DO
    Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin.
    Suzuki H; Kim SH; Tanara M; Okazaki K; Okabe T; Wu RT; Tanaka N
    Cancer Res; 1987 Feb; 47(3):713-7. PubMed ID: 3467840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Criticism of pharmacokinetic clearance concepts.
    Keller F; Schoole J
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):563-8. PubMed ID: 6654532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolism.
    Karp JE; Donehower RC; Dole GB; Burke PJ
    Cancer Res; 1984 Nov; 44(11):5046-50. PubMed ID: 6488163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic studies of tritiated cytosine arabinoside (NSC-63878) in children.
    Finklestein JZ; Scher J; Karon M
    Cancer Chemother Rep; 1970 Feb; 54(1):35-9. PubMed ID: 5538163
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics.
    Pommier Y; Pochat L; Marie JP; Zittoun RA
    Cancer Treat Rep; 1983 Apr; 67(4):371-3. PubMed ID: 6850654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a relationship between cytarabine pharmacokinetics and keratitis?--A case report.
    Boos J; Bömelburg T; Gerding H; Jürgens H
    Int J Clin Pharmacol Ther Toxicol; 1993 Dec; 31(12):593-6. PubMed ID: 8314360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA from herpes simplex virus resistant to 9-beta-D-arabinofuranosyladenine.
    Kufe D; Herrick D; Crumpacker C; Schnipper L
    Cancer Res; 1984 Jan; 44(1):69-73. PubMed ID: 6317173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days.
    Kreis W; Chaudhri F; Chan K; Allen S; Budman DR; Schulman P; Weiselberg L; Freeman J; Deere M; Vinciguerra V
    Cancer Res; 1985 Dec; 45(12 Pt 1):6498-501. PubMed ID: 3864533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of the concepts of "half-life" and "clearance" in practice and in pharmacokinetics].
    Raaflaub J
    Schweiz Med Wochenschr; 1981 Sep; 111(38):1406-11. PubMed ID: 7280641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.